Evoke Announces Agreement with Mallinckrodt to Amend Milestone Payments
“We continue to focus our current resources on the NDA submission and commercial preparation of Gimoti and appreciate Mallinckrodt’s support of Evoke and our intent to bring Gimoti to market. This deferral provides us additional available capital. We have now improved our cash runway to January of next year and remain on track to submit the Gimoti NDA next quarter,” commented
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company is developing Gimoti, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in
Safe Harbor Statement
Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negatives of these terms or other similar expressions. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding: anticipated timing to submit an NDA for Gimoti; the potential timing of
Source: Evoke Pharma, Inc.